CLOCK and cancer: Our findings place TH301 in a unique position, as a novel, powerful, and promising agent, for further development of new regimens dedicated to treatment of PDAC, and presumably other baneful cancers, whereat circadian clock disruption serves as a contributing factor to disease initiation, progression, metastasis, and/or chemoresistance.